These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 7237894

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW.
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Non-invasive radiocardiographic assessment of the effects of prazosin in congestive heart failure.
    Nakajima H, Yui Y, Kawashita K, Yoshida A, Kawai C.
    Jpn Circ J; 1982 May; 46(5):468-72. PubMed ID: 7077811
    [Abstract] [Full Text] [Related]

  • 25. Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure.
    LeJemtel TH, Elkayam U, Ribner HS, Hellman C, Strom J, Frishman W, Strobeck J, Sonnenblick EH.
    Eur Heart J; 1980 Jun; 1(3):157-63. PubMed ID: 7026250
    [No Abstract] [Full Text] [Related]

  • 26. [Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].
    Wirtzfeld A, Klein G, Himmler FC, Schmidt G, Kutschera I, Sauer E.
    Dtsch Med Wochenschr; 1980 Oct 03; 105(40):1379-83. PubMed ID: 7449633
    [Abstract] [Full Text] [Related]

  • 27. Vasodilators and ventricular septal defect: comparison of prazosin, minoxidil, and hydralazine in a chronic lamb model.
    Boucek MM, Chang R, Synhorst DP.
    Pediatr Res; 1984 Sep 03; 18(9):859-64. PubMed ID: 6483509
    [Abstract] [Full Text] [Related]

  • 28. Oral hydralazine therapy for chronic refractory heart failure.
    Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A.
    Circulation; 1976 Dec 03; 54(6):879-83. PubMed ID: 825327
    [Abstract] [Full Text] [Related]

  • 29. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.
    Elkayam U, Lejemtel TH, Mathur M, Ribner HS, Frishman WH, Strom J, Sonnenblick EH.
    Am J Cardiol; 1979 Sep 03; 44(3):540-5. PubMed ID: 474434
    [No Abstract] [Full Text] [Related]

  • 30. Vasodilator therapy of chronic congestive heart failure.
    Cabaniss CD.
    J Med Assoc Ga; 1980 Feb 03; 69(2):131-2. PubMed ID: 7373170
    [No Abstract] [Full Text] [Related]

  • 31. Effect of prostacyclin and prazosin in the treatment of congestive heart failure; with special reference to the sympathetic nervous system.
    Yui Y, Sakurai T, Nakajima H, Kawai C.
    Jpn Circ J; 1984 Apr 03; 48(4):365-72. PubMed ID: 6371282
    [Abstract] [Full Text] [Related]

  • 32. Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.
    Packer M, Meller J, Gorlin R, Herman MV.
    Am J Cardiol; 1979 Aug 03; 44(2):310-7. PubMed ID: 463769
    [Abstract] [Full Text] [Related]

  • 33. Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.
    Rubin SA, Chatterjee K, Parmley WW.
    Circulation; 1980 Mar 03; 61(3):543-8. PubMed ID: 7353245
    [No Abstract] [Full Text] [Related]

  • 34. Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
    Armstrong PW.
    Can Med Assoc J; 1979 Oct 06; 121(7):913-8. PubMed ID: 497982
    [Abstract] [Full Text] [Related]

  • 35. [Hemodynamic changes caused by prazocin in patients with uncomplicated arterial hypertension].
    Ban Hayashi E, Meaney E, Rivera JM.
    Arch Inst Cardiol Mex; 1983 Oct 06; 53(4):357-62. PubMed ID: 6639214
    [Abstract] [Full Text] [Related]

  • 36. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN.
    Circulation; 1993 Jun 06; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [Abstract] [Full Text] [Related]

  • 37. Acute and chronic haemodynamic effects of prazosin in left ventricular failure.
    Stein L, Foster PR, Friedman AW, Statza J, McHenry PL.
    Br Heart J; 1981 Feb 06; 45(2):186-92. PubMed ID: 7459177
    [Abstract] [Full Text] [Related]

  • 38. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
    Packer M, Medina N, Yushak M.
    J Am Coll Cardiol; 1986 Mar 06; 7(3):671-80. PubMed ID: 2869077
    [Abstract] [Full Text] [Related]

  • 39. Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure.
    Colucci WS, Holman BL, Wynne J, Carabello B, Malacoff R, Grossman W, Braunwald E.
    Am J Med; 1981 Jul 06; 71(1):75-80. PubMed ID: 6113759
    [Abstract] [Full Text] [Related]

  • 40. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH.
    N Engl J Med; 1986 Jun 12; 314(24):1547-52. PubMed ID: 3520315
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.